Manufacturer updates

Effective April 17th, 2023, AbbVie will only provide 340B priced product to a single Contract Pharmacy located within 40 miles of the parent site if a hospital covered entity doesn’t have an in-house pharmacy. Federal Grantees not subject to limitations. *Updated policy now includes 90 drugs from original 25 added to exclusion list

Effective April 11th, 2023, Amgen will only provide 340B priced product to a single Contract Pharmacy located within 40 miles of the parent site if the non-grantee doesn’t have an in-house pharmacy. Federal Grantees not subject to limitations.

support@340Besp.com

Effective September 1st, 2023, Astellas will only provide 340B pricing for Xtandi® to a single contract pharmacy if a hospital covered entity doesn’t have an in-house pharmacy. Federal Grantees not subject to limitations.  

Contact: 
support@340BESP.com

Effective August 1st, 2023, AstraZeneca will transition the administration of their 340B contract pharmacy program to a third-party vendor.

Contact: 
support@340BESP.com 

*Calquence & Lynparza (October 1st, 2022) and Fasenra (January 1st, 2023) voluntary contracts restored.

Effective October 1st, 2020, AstraZeneca will only provide 340B priced product to a single Contract Pharmacy.

Contact: membership@AstraZeneca.com 

Effective June 26th, 2023, Bausch Health will only provide 340B priced products to a single contract pharmacy located within 40 miles of the parent site if the entity does not have an in-house pharmacy. 

Effective August 1st, 2022, Bausch Health will only provide 340B priced product to a single Contract Pharmacy if Covered Entity doesn’t have an in-house pharmacy. Multiple contract pharmacy access is permissible through provision of claims data via 340B ESP. 

Contact:
support@340Besp.com

Effective June 1st, 2023, Bayer will only provide 340B priced product to a single Contract Pharmacy located within 40 miles of the parent site if a hospital covered entity doesn’t have an in-house pharmacy. Federal Grantees not subject to limitations.

*Updated policy now includes Adempas

Effective March 1, 2023, Bayer will only provide 340B priced product to a single Contract Pharmacy location if the hospital Covered Entity does not have an in-house pharmacy. Multiple contract pharmacy access is permissible through provision of claims data via 340B ESP. Grantees not subject to limitations.

Effective February 1st, 2023, Biogen will only provide 340B priced product to a single Contract Pharmacy location if the Covered Entity does not have an in-house pharmacy. Policy is limited to two drugs and doesn’t include Federal Grantees.

Effective August 1st, 2023, Boehringer Ingelheim will only provide 340B priced products to a single contract pharmacy located within 40 miles of the parent site if the entity does not have an in-house pharmacy. No central fill pharmacies.

Any covered entity that does not have an in-house pharmacy capable of dispensing specialty products may designate 1 specialty pharmacy from within BI’s limited distribution network for the purpose of dispensing OFEV.

Boehringer Ingelheim announced effective September 1st, 2022, an expansion to their contract pharmacy policy to include grantees enrolled in the Consolidated Health Center Program (CH/CHC). All other Federal Grantees not subject to limitations.

Contact:
support@340besp.com

Effective December 1st, 2021, BI will add its specialty product, OFEV, to the list of products subject to its 340B Contract Pharmacy policy. BI restrictions from August 1st, 2021, remain effective. Link to both notices below. 

Contact:
support@340Besp.com

*Camzyos effective July 1st, 2022 

At this time, Clovis won’t be implementing its partnership with Kalderos to effectuate 340B drug discounted prices for 340B Contract Pharmacies. Clovis’ products remain available through all historically available channels.

Contact:
priceadmin@clovisoncology.com

Effective September 1st, 2020, Lilly restricted access for 340B priced product to Contract Pharmacies, except insulin.

Contact:
340B@lilly.com

Effective October 1st, 2023, EMD Serono’s updated contract pharmacy policy will include all EMD Serono marketed Products. EMD Serono will only provide 340B pricing products to a single contract pharmacy if a hospital covered entity doesn’t have an in-house pharmacy. 

*Serostim^®: covered entities may designate one additional contract pharmacy location in EMDS’s secure distribution network (the “SND”) for the purpose of dispensing Serostim only.   

Federal Grantees not subject to limitations.

Contact: 
support@340besp.com  

Effective March 1, 2023, EMD Serono (EMDS) will only provide 340B pricing for REBIF and GONAL-F to a single Contract Pharmacy if a hospital Covered Entity does not have an in-house pharmacy location. Grantees not subject to limitations.

Effective May 1, 2023, GSK will only provide 340B priced product to a single Contract Pharmacy if a covered entity doesn’t have an in-house pharmacy. An additional specialty pharmacy part of a limited pharmacy network may be designated.

*Updated policy now includes all GSK drugs

Contact:

support@340BESP.com

Effective July 1st, 2022, GSK will no longer offer voluntary 340B pricing on two orphan drugs (NUCALA and ZEJULA) to Covered Entities subject to the 340B orphan drug exclusion. This change will not impact Covered Entities not subject to the orphan drug exclusion.

Contact:
US.340B@gsk.com 

Effective October 16th, 2023, Incyte will only provide 340B pricing on Opzelura^® to a single contract pharmacy located within 40 miles of the parent site if a hospital entity does not have an in-house pharmacy.

Federal Grantees are not subject to limitations.

Effective October 9th, 2023, Jazz will only provide 340B pricing for Epidiolex^® to a single contract pharmacy if a hospital covered entity doesn’t have an in-house pharmacy. 

Federal Grantees not subject to limitations.

Contact: 
support@340besp.com 

Effective July 31st, 2023, Merck will provide 340B priced products to an unlimited number of contract pharmacies in the state of Louisiana and Arkansas if the hospital or CH covered entity registers and submits 340B claims data. Federal Grantees (except CH grantee entities) not subject to limitations.  

Contact: 
340bdata@merck.com

Effective June 12, 2023, Merck will only provide 340B priced product to a single contract pharmacy location, within 40 miles of the hospital Covered Entity or Consolidated Health Center, if they don’t have an in-house pharmacy. All other Federal Grantees are not subject to limitations. 

Effective September 1st, 2021, Merck will only provide 340B priced product to a single Contract Pharmacy if the Covered Entity does not have an in-house pharmacy location. Grantees not subject to limitations. 

Contact:
340Bdata@merck.com

Effective May 1st, 2023, Novartis will only provide 340B priced product to a single Contract Pharmacy if the hospital covered entity doesn’t have an in-house pharmacy. Federal Grantees not subject to limitations.

Contact:

Novartis.340B@novartis.com

Effective July 1st, 2023, Novo Nordisk will allow up to two contract pharmacy locations per 340B hospital (one retail, one specialty). Federal Grantees are not subject to limitations.

340BInfo@novonordisk.com

Effective July 1st, 2023, Organon will only provide 340B priced product to a single contract pharmacy location if the hospital Covered Entity provides Claims Level Detail via 340B ESP platform. Federal Grantees not subject to limitations.

Effective November 1st, 2023, Pfizer will change its process on acquiring Vyndamax^® and Vyndaquel^® at the 340B ceiling prices. A 340B covered entity may either apply to have its specialty pharmacy be a VYNDA Network Institution or establish a contract pharmacy relationship with a specialty contract pharmacy in the VYNDA Network.

Federal Grantees not subject to limitations.

Contact: 
340BCP@pfizer.com

Effective May 1st, 2023, Pfizer will only provide Xeljanz at a 340B price to a single Contract Pharmacy if the hospital covered entity doesn’t have an in-house pharmacy. Federal Grantees not subject to limitations.

*No modifications to Pfizer’s DON policy

Contact:

340BCP@pfizer.com

Effective June 1, 2023, Sanofi will only provide 340B priced product to a single contract pharmacy location if the hospital Covered Entity doesn’t have an in-house pharmacy. Federal Grantees, Children’s Hospitals, and Free Standing Cancer Hospitals are not subject to limitations. 

Effective August 1st, 2023, Teva will provide 340B priced products to an unlimited number of contract pharmacies in the state of Louisiana. Federal Grantees not subject to limitations. 

Contact: 
support@340Besp.com

Effective July 5th, 2023, Teva will only provide 340B priced products to a single contract pharmacy located within 40 miles of the parent site if the non-grantee entity does not have an in-house pharmacy. Federal Grantees not subject to limitations.

Contact: 
support@340Besp.com

Effective October 2nd, 2023, UCB updated its contract pharmacy policy to exclude wholly owned (and common ownership) pharmacy exemption. UCB will only provide 340B pricing to a single contract pharmacy located within 40 miles of the parent site if a hospital covered entity doesn’t have an in-house pharmacy.

Federal Grantees not subject to limitations.

Effective December 13th, 2021, UCB will only provide 340B priced product to a single Contract Pharmacy if the Covered Entity does not have an in-house pharmacy location. Federal Grantees not subject to limitations.

Contact:
support@340Besp.com

Effective April 1, 2023, select Woodward Pharma products will only be available at a 340B ceiling price through direct distribution via DCS and no longer available via full line distributor 340B accounts.

*12 additional NDCs effective March 15th, 2023

Contact: 
340b-clientsservices@
directcustomersolutions.com